News Overview

RenovaroCube to Acquire 100% Ownership of Cyclomics

April 24, 2024

RenovaroCube to Acquire 100% Ownership of Cyclomics

RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment.

Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board

April 18, 2024

Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board

This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.

Statement of Renovaro Inc

February 14, 2024

Statement of Renovaro Inc

We felt compelled to comment on the shorter Hindenburg’s opinion piece.

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

February 13, 2024

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.

AI Pioneer GEDiCube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine

February 13, 2024

AI Pioneer GEDiCube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine

“We believe this combination marks a significant milestone in the journey of personalized medicine,”

Results Shareholders Meeting

January 25, 2024

Results Shareholders Meeting

All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated January 3, 2024, were approved by the requisite number of votes cast at the meeting.

Message from CEO The Hon. Mark Dybul, MD

January 16, 2024

Message from CEO The Hon. Mark Dybul, MD

I write to update you on our key developments towards precision medicine for healthy longevity - starting with cancer - powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery towards our vision of a world with effective cancer treatments free from toxic chemotherapy.

Avram Miller joins Renovaro Board

October 11, 2023

Avram Miller joins Renovaro Board

Renovaro Biosciences Inc, has announced that Avram Miller will join its Board of Directors.

Appointment of Finance Experts

October 10, 2023

Appointment of Finance Experts

Renovaro recently announced a definitive agreement to combine with the advanced AI Company GEDi Cube Intl Ltd. GEDiCube intends to rebrand as Renovaro AI, as announced on September 29, 2023.

Message from CEO The Hon. Mark Dybul MD

October 2, 2023

Message from CEO The Hon. Mark Dybul MD

I am writing to provide you with an update on our recent news of signing a definitive agreement to combine with GEDiCube (GEDiCube Press Release) (Renovaro Press Release)...